A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement

AIM: We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement. METHODS: Pati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Asia Pac J Clin Oncol
Main Authors: Harada, Daijiro, Kozuki, Toshiyuki, Nogami, Naoyuki, Bessho, Akihiro, Hosokawa, Shinobu, Fukamatsu, Nobuaki, Hotta, Katsuyuki, Ohashi, Kadoaki, Kubo, Toshio, Yoshioka, Hiroshige, Yokoyama, Toshihide, Sone, Naoyuki, Kuyama, Shoichi, Kudo, Kenichiro, Yasugi, Masayuki, Takigawa, Nagio, Oze, Isao, Kiura, Katsuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6849786/
https://ncbi.nlm.nih.gov/pubmed/30938103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13147
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados